Details of the Drug Reposition

General Information of This Drug (ID: DMW5V4U)

Drug Name
Enfortumab vedotin   DMW5V4U
Synonyms Padcev
Drug Type
Antibody drug conjugate

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urothelial carcinoma DISRTNTN 2C92.0 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bladder cancer DISUHNM0 2C94 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website.
2 ClinicalTrials.gov (NCT03474107) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). U.S.National Institutes of Health.